Pricing Log in Create free account

Pyxis Oncology, Inc. (PYXS) vs Atrium Therapeutics, Inc. (RNA)

Pyxis Oncology, Inc. and Atrium Therapeutics, Inc. are both Biotechnology companies. Pyxis Oncology, Inc. and Atrium Therapeutics, Inc. are of similar size ($198.6M and $185.8M). Pyxis Oncology, Inc. has the higher net margin (0.00% vs −203.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Atrium Therapeutics, Inc. leads on 7 and Pyxis Oncology, Inc. on 4.

Valuation

Metric PYXS RNA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 5.08 9.40
P/B 9.29 0.66 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 2.03 0.66
EV/Sales n/m (4.33) 9.02
Earnings yield (84.94%) (40.03%) (32.88%)
Free cash flow yield (63.94%) (40.71%) (23.13%)

Profitability

Metric PYXS RNA Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (214.60%) 0.00%
Net margin 0.00% (203.67%) 0.00%
Free cash flow margin 0.00% (206.99%) 0.00%
Return on equity (179.10%) 0.00% (51.96%)
Return on assets (99.62%) (40.74%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PYXS RNA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 3.03% — 29.88%
Revenue growth, 5-year CAGR — 22.54% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PYXS RNA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.34 8.73 4.97
Net debt to EBITDA 0.82 9.08 1.01

Dividend

Metric PYXS RNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PYXS RNA Biotechnology median
Market cap 198.55m 185.78m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack